Kelly Lawrence W & Associates Inc. CA Buys Shares of 59,250 Repligen Corporation $RGEN

Kelly Lawrence W & Associates Inc. CA bought a new position in Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, Holdings Channel.com reports. The fund bought 59,250 shares of the biotechnology company’s stock, valued at approximately $8,084,000. Repligen comprises approximately 1.7% of Kelly Lawrence W & Associates Inc. CA’s investment portfolio, making the stock its 20th biggest holding.

Several other hedge funds also recently modified their holdings of RGEN. Avidity Partners Management LP boosted its holdings in Repligen by 54.7% in the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares in the last quarter. Swedbank AB bought a new position in Repligen during the fourth quarter valued at about $4,146,000. B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Repligen in the second quarter worth about $3,597,000. Conestoga Capital Advisors LLC lifted its position in shares of Repligen by 10.6% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after buying an additional 101,062 shares during the last quarter. Finally, Global Retirement Partners LLC bought a new stake in shares of Repligen during the 2nd quarter worth about $655,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $181.62 on Tuesday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The stock has a market capitalization of $10.25 billion, a PE ratio of 248.79, a P/E/G ratio of 3.31 and a beta of 1.03. The stock has a 50-day simple moving average of $148.17 and a 200 day simple moving average of $131.97.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Research analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on RGEN. HSBC lowered their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. Wells Fargo & Company increased their price target on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, Evercore restated an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $166.43.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.